-
Myriocin Reprograms dAGE-Induced Metabolic Dysfunction
2026-09-07
A 2025 Nutrients study shows that Myriocin counteracts high dietary advanced glycation end product exposure in mice by linking sphingolipid synthesis inhibition to AMPK–PGC1α-driven mitochondrial activation. The findings connect improved glucose and lipid homeostasis with reduced steatosis, adipose accumulation, lipogenesis, and enhanced thermogenesis, while also defining important limits for translation beyond the mouse model.
-
MRT68921 ULK1 Kinase Inhibitor Guide
2026-09-05
MRT68921 is a potent dual ULK1/2 kinase inhibitor that blocks autophagy initiation through ULK1-dependent signaling. Its reported effects on ATG13 phosphorylation and LC3 flux support use as a research tool for dissecting the autophagy signaling pathway, but the compound remains preclinical and is not a medical product.
-
Pretomanid and Terminal Oxidase Inhibition in TB
2026-09-05
The reference study identifies dual inhibition of the cytochrome bcc:aa3 and cytochrome bd terminal oxidases as a central feature of pretomanid activity in Mycobacterium tuberculosis. Its combination data support rational regimens pairing pretomanid with respiratory inhibitors to increase bactericidal activity and reduce the likelihood of resistance emergence.
-
Balsalazide in Active Ulcerative Colitis: Evidence Review
2026-09-04
The 2009 review evaluates balsalazide as a bacteria-activated 5-aminosalicylate prodrug designed to deliver 5-ASA throughout the colon. Its synthesis of clinical and pharmacologic evidence supports efficacy for remission induction in mild-to-moderate active ulcerative colitis, with a favorable safety profile and potentially faster symptom improvement than mesalamine.
-
Oligo (dT) 25 Beads: Practical mRNA Capture
2026-09-04
Oligo (dT) 25 Beads provide a magnetic workflow for capturing polyadenylated eukaryotic mRNA from total RNA or lysates prepared from animal and plant cells and tissues. They are appropriate for polyA-selected mRNA workflows, but not for comprehensive recovery of non-polyadenylated RNA or as a substitute for total-RNA purification when ribosomal, noncoding, or bacterial RNA is the primary target.
-
RIPA Lysis Buffer Strong for BAT Protein Workflows
2026-09-03
Use RIPA Lysis Buffer Strong to extract proteins from adipose tissue and cultured cells when broad detergent solubilization and customizable inhibitor control are priorities. This workflow translates brown adipose tissue thermogenesis findings into practical Western blot, immunoprecipitation, ELISA, and kinase-assay sample preparation strategies.
-
BAPTA for Calcium Signaling and Apoptosis
2026-09-03
BAPTA converts an otherwise difficult-to-interpret calcium signal into a testable causal variable for apoptosis research, toxicology, and cell signaling studies. This workflow shows how to pair calcium chelation with IP3R and STAT3 controls, exposure models, and troubleshooting safeguards.
-
HyperScript RT SuperMix: From RNA to Insight
2026-09-02
HyperScript RT SuperMix for qPCR supports reproducible cDNA synthesis when RNA structure and abundance complicate gene expression analysis. This article connects reverse-transcription design with mechanistic interpretation of a finger citron–NAFLD study, showing how assay architecture can strengthen biological conclusions.
-
G007-LK Tankyrase 1/2 Inhibitor Workflows
2026-09-02
Build reproducible Wnt/β-catenin and Hippo-pathway experiments with G007-LK, from dose-response screening to mechanistic validation. The workflow connects APC-mutant colorectal cancer models with a reference-supported hepatocellular carcinoma use case, while emphasizing solvent control, orthogonal readouts, and troubleshooting.
-
Sulforaphane, PM2.5, and COPD Signaling
2026-09-01
This study links sulforaphane protection against PM2.5-induced COPD to coordinated activation of Nrf2 antioxidant signaling and suppression of EGFR/PI3K/AKT activity. Its combination of rat and cell models, network pharmacology, molecular docking, and EGFR silencing provides a mechanistic framework for studying oxidative injury and intervention response.
-
Thiamet G: From O-GlcNAc to Translational Strategy
2026-08-31
Thiamet G offers a controlled way to interrogate O-GlcNAc biology across tauopathy, oncology, and bone research. This thought-leadership guide connects O-GlcNAcase inhibition with Wnt-driven glycolysis and provides practical guidance for translating pathway modulation into robust experimental decisions.
-
PBA-Modified PAD4 Inhibitors Block Tumor NETs
2026-08-31
The reference study developed phenylboronic acid–modified PAD4 inhibitors that preferentially target tumor-associated environments while suppressing the PAD4–H3cit–NET pathway. Its lead compound reduced tumor growth and metastasis in mouse models and altered immune-cell composition, providing a preclinical framework for more selective PAD4 inhibition.
-
Imatinib Hydrochloride: A Phosphatase-Aware View
2026-08-30
Imatinib hydrochloride, also known as STI571 hydrochloride, is examined here through a phosphatase-aware framework for interpreting kinase inhibition. This article connects Abl, c-Kit, and PDGFR blockade with conformational control, assay design, and the limits of translating p38α mechanistic findings into cancer research.
-
4-Hydroxytamoxifen B6167: Workflow Guide
2026-08-29
4-Hydroxytamoxifen (B6167) is an estrogen receptor modulator for controlled DMSO-based experiments in breast cancer research, prostate cancer research, apoptosis assays, and cardiac myocyte studies. It should not be selected for workflows that require aqueous or ethanol solubility, and solid-state storage is preferred over long-term storage of prepared solutions.
-
EGCG Nanoparticles Strengthen FLASH-RT
2026-08-29
The reference study developed functionalized, self-assembled EGCG nanoparticles, termed BENPs, to increase tumor-cell oxidative damage during FLASH-RT. In a 4T1 breast cancer model, BENPs enhanced ROS-associated DNA damage, apoptosis, tumor control, and antitumor immune activation while showing encouraging preliminary biosafety.